Posted on Leave a comment

Bill on Medical Cannabis Legalization Passes First Reading in Ukrainian Parliament*

Flag of Ukraine

« This bill is not so much about medicine as about the industrial cultivation of cannabis and corruption schemes by the government regarding permits and the development of huge financial flows. »*

People’s deputy Iryna Herashchenko

Before the bill can become law, it must pass a second reading following any amendments and necessary finalization before being sent to the president for his signature, reports Kyiv Post.*

Ukraine’s parliament has given its initial approval to a bill aiming to legalize medical cannabis in the country. People’s deputies Iryna Herashchenko and Yaroslav Zheleznyak confirmed the successful vote, with 268 deputies supporting the legislation. *

“The long-awaited bill on medical cannabis has passed the first reading. But this bill is not so much about medicine as about the industrial cultivation of cannabis and corruption schemes by the government regarding permits and the development of huge financial flows,” Iryna Herashchenko wrote.*

However, before the bill can become law, it must pass a second reading following any necessary finalization and subsequently be sent to the president for his signature.*

President Volodymyr Zelensky has already expressed his support for the bill, urging parliamentarians to vote in favor of it at the end of June.*

The draft law put forward by the Ministry of Health outlines several key provisions. First and foremost, it proposes establishing a licensing system for the cultivation of cannabis strains intended for medical purposes.*

Entities seeking to engage in the cultivation of cannabis for medical, industrial, or scientific and technical activities will be required to obtain the appropriate permit.*

Furthermore, the bill advocates to strict monitoring of the production and distribution of medical cannabis and related products. Each batch of medication will be labelled with a unique barcode, ensuring comprehensive tracking throughout the supply chain.*

Additionally, the proposal calls for the implementing of an electronic register to record the movement of medical cannabis. Patients will only be able to access cannabis-based medications with a valid prescription from a qualified medical professional based on a relevant medical diagnosis.*

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

German government gives green light to legalizing recreational cannabis*

Flag of Germany

« For minors, consumption remains prohibited and for young adults (up to 21 years old), it is limited. »

Health Minister Karl Lauterbach

Germany took a further step towards the legalization of cannabis for recreational purposes on Wednesday with the adoption by the Council of Ministers of the bill, which will be accompanied by a prevention campaign aimed at young people, reports RTS.*

According to the text, which has yet to be debated and voted on by parliament, it will be possible from the age of 18 to buy and possess up to 25 grams of cannabis. Germany will thus have one of the most liberal legislations in Europe, following in the footsteps of Malta and Luxembourg, which legalized recreational cannabis in 2021 and 2023 respectively.*

The coalition of the social democrat of Olaf Scholz with the Greens and the Liberals made this legalization one of the flagship projects of his mandate even if the initial plan went much further. Faced with the reservations of the European Union, Berlin had to review its copy. *

The reform also arouses criticism from the opposition, police unions or judges who believe that it will not put an end to trafficking, when it is one of the objectives.*

According to this bill, it will also be possible to cultivate up to three cannabis plants for one’s own use.*

Cannabis clubs*

The new legislation provides for the creation of non-profit associations whose adult members – their number is limited to 500 – will be able to cultivate the plant for their own consumption, under the supervision of the public authorities.*

These “Cannabis Social Clubs” – as they call themselves – will have a regulated activity: they will only be able to supply their members and at the rate of 25 grams per day with a maximum of 50 grams per month. For young people aged 18-21, it will be a little less: 30 grams per month. These clubs will be subject to controls by the public authorities.*

The consumption of cannabis must be outside these clubs and will be prohibited within 200 meters of these clubs, schools, playgrounds, sports fields and associations for young people.*

Youth awareness*

Health Minister Karl Lauterbach also plans to launch a major awareness campaign aimed at young people on the dangers of cannabis for the brain “particularly harmful when it is still in a period of growth”.*

“For minors, consumption remains prohibited and for young adults (up to 21 years old), it is limited,” he said in a statement.*

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

Health Ministry: From December, doctors can prescribe marijuana*

Flag of Israel

« Up until now, those eligible for medical marijuana had to get a special license. »

Israeli health ministry

Approval of the plan would be the first step to legalising possession of limited amounts of the drug and allow ‘cannabis club’ members to buy it for recreational purposes, reports The Times of Israel.*

The Health Ministry says that from December, doctors will be able to prescribe marijuana to patients.*

The ministry publishes its reforms into the medical marijuana system, saying that it will review the system again after a year.*

The reform is intended to make it easier for patients to access the drug and remove bureaucratic hurdles. Up until now, those eligible for medical marijuana had to get a special license.*

The reform also removes CBD products that do not have psychoactive properties, from drug restrictions.*

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

German Cabinet set to approve plans to liberalise cannabis rules*

Flag of Germany

« …adults allowed to possess up to 25 grams of the drug and grow a maximum of three plants for personal use. »

german government

Approval of the plan would be the first step to legalising possession of limited amounts of the drug and allow ‘cannabis club’ members to buy it for recreational purposes, reports Euronews.*

Germany is set to approve a plan to liberalise the country’s rules on cannabis, which could see adults allowed to possess up to 25 grams of the drug and grow a maximum of three plants for personal use.*

Cabinet approval, expected on Wednesday, has been billed as the first step in a two-part plan and will still need to be ratified by Parliament.*

If finalised, it would also allow the drug to be cultivated and sold by “cannabis clubs” to its members for recreational purposes.*

The proposed plan is a stride forward for a prominent reform project of Chancellor Olaf Scholz’s socially liberal coalition, though significantly short of the government’s original ambitions.*

Officials hope legalisation will help push back the black market, protect consumers against contaminated products, and reduce drug-related crime.*

But the plan faces opposition from several quarters.*

The centre-right opposition believes the government is pressing ahead with legalising a risky drug despite European legal obstacles and expert opinion.*

And an organisation representing German judges says the proposed law is likely to increase rather than decrease the burden on the judicial system.*

The government said it plans to follow the new legislation with a second step which would see five-year tests of regulated commercial supply chains in select regions.*

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

The marketing of cannabis in the canton of Bern should start in the fall*

Flag of Switzerland

« The pilot trial and the follow-up study aim to assess the health and social effects of selling cannabis in pharmacies. »

Reto Auer, project manager at the University of Bern

The Bernese pilot trial for the regulated sale of cannabis in pharmacies will be able to start. The Federal Office of Public Health (OFSP), the Cantonal Ethics Commission and the Ethics Commission of North-West and Central Switzerland have issued the necessary authorisations, reports the RTS.*

The pilot trial and the follow-up study aim to assess the health and social effects of selling cannabis in “strictly regulated and non-profit” pharmacies, recalls Reto Auer, project manager at the University of Bern, quoted Wednesday in a press release from the university.*

The study will be conducted in the cities of Bern, Biel and Lucerne. It should start “probably in the fall”. It is planned to recruit 1091 participants, including about 600 in the federal city, specifies the latter.*

People who regularly use cannabis for recreational purposes and who are at least 18 years old can participate in the study.*

Similar studies have already been authorized in Basel, Zurich, Lausanne and Geneva.*

* original article

** image

*** ndlr. : –.

Posted on Leave a comment

Endocannabinoid Signaling Regulates Sleep Stability*

PLOS ONE logo
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

Medical Cannabis and Cannabinoids for Impaired Sleep: A Systematic Review and Meta-Analysis of Randomized Clinical Trials*

logo Sleep
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

Cannabis use in patients with insomnia and sleep disorders: Retrospective chart review

logo CPJRPC
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

Treating Insomnia Symptoms with Medicinal Cannabis: A Randomized, Cross-Over Trial of the Efficacy of a Cannabinoid Medicine Compared with Placebo

logo Sleep®
Désolé, vous n’êtes pas autorisé-e à voir ce contenu. Pour voir cette page, il  faut vous connecter à votre compte avec privilège.

Sorry, you are not authorized to view this content. To view this page, you must log into your account with privilege.

Login

NOUVELLE INSCRIPTION / NEW REGISTRATION

Si vous n’avez pas encore de compte avec privilège, il est nécessaire de nous envoyer une demande spécifique par courriel (info@86avenue.ch) après création d’un compte standard. Des justificatifs pourrons vous être demandés, confirmant votre statut de personne impliquée dans le domaine médical ou titulaire d’une autorisation. Un privilège sera ensuite attribué à votre profil.

Vous pouvez également remplir le FORMULAIRE D‘INSCRIPTION pour l’obtention du privilège. Ce service est TOTALEMENT GRATUIT.

En vous enregistrant sous votre profil avec privilège, vous pourrez accéder aux articles médicaux et assimilés, ainsi qu’à leurs résumés. Nous regrettons cette situation qui pourrait exposer notre entreprise à des sanctions légales.

 

If you do not yet have a privileged account, it is necessary to send us a specific request by email (info@86avenue.ch) after creating a standard account. Evidence may be requested, confirming your status as a person involved in the medical field or holder of an authorization. A privilege will then be assigned to your profile.

You can also complete the REGISTRATION FORM for obtaining the privilege. This service is TOTALLY FREE.

By registering under your profile with privilege, you will be able to access medical and similar articles, as well as their summaries. We regret this situation which could expose our company to legal sanctions.

Posted on Leave a comment

The cannabis sales regulation project validated in the canton of Vaud*

Flag of Switzerland

« The effects of regulated non-profit cannabis sales on consumer behavior and its impact on the illegal market. »

Emilie Moeschler, municipal in social cohesion

The Lausanne project for the regulated sale of cannabis is taking shape. Entitled Cann-L, the pilot trial has received authorization from the Federal Office of Public Health, thus joining the projects already validated in Basel and Zurich, reports the RTS.*

People wishing to participate in this study – 2000 have already expressed their interest on the project’s website – will be able to register in June. The place of sale, which is not yet known, should open in September, the City of Lausanne indicated on Tuesday.* The Vaudois capital and its partner Addiction Suisse, which is leading the scientific part of the project, hope to bring together a panel of around 1,200 people who use cannabis and live in Lausanne.*

The products will be available in a single point of sale and without medical connotation. Several premises are currently being evaluated.* The sales team is being formed. This will provide advice on consumption and risk reduction, as well as reminders on the legislation in force. It will also be able to “evaluate and guide people with problematic consumption in the support network”, specifies the City of Lausanne.*

On sale by September*

“After the Cantonal Ethics Commission, the authorization of the OFSP marks a major step for our project”, commented Emilie Moeschler, the municipal councilor for social cohesion, quoted in the press release. She added that the concrete phase could now start with, as a first step, the launch of registrations.*

Necessary for the study, the “local and organic” cultivation of the plants can also begin. The first harvest will take place during the summer. This will be followed by a period of preparation of the products before they go on sale by September.*

These products will be intended “for personal consumption and in the private sphere”, underlines the Vaud capital. And to recall that it seeks to study, via this pilot project, “the effects of the regulated sale of non-profit cannabis on the behavior of consumers as well as its impact on the illegal market.”*

The project should thus make it possible to better understand consumption, but also strengthen prevention. In terms of security, it is a question of limiting the nuisance caused by the illegal market.*

* original article

** image

*** ndlr. : –.